28 / 148
28
Informaciones
Psiquiátricas
2018 - n.º
232
Bibliografía
1. Silverman DH, Small GW, Chang CY, Lu
CS, Kung De Aburto MA, Chen W, et al.
Positron emission tomography in eva-
luation of dementia: Regional brain me-
tabolism and long-term outcome. JAMA.
2001;286:2120-2127.
2. Jagust W, Reed B, Mungas D, Ellis W,
Decarli C. What does fluorodeoxyglucose
PET imaging add to a clinical diagnosis
of dementia? Neurology. 2007;69:871-
877.
3. Mosconi L, Mistur R, Switalski R, Tsui
WH, Glodzik L, Li Y, et al. FDG-PET chan-
ges in brain glucose metabolism from
normal cognition to pathologically veri-
fied Alzheimer's disease. Eur J Nucl Med
Mol Imaging. 2009;36:811-822.
4. Caselli RJ, Chen K, Lee W, Alexander GE,
Reiman EM. Correlating cerebral hypo-
metabolism with future memory decline
in subsequent converters to amnestic
pre-mild cognitive impairment. Arch
Neurol. 2008;65:1231-1236.
5. Del Sole A, Clerici F, Chiti A, Lecchi M,
Mariani C, Maggiore L, et al. Individual
cerebral metabolic deficits in Alzheimer's
disease and amnestic mild cognitive im-
pairment: an FDG PET study. Eur J Nucl
Med Mol Imaging. 2008;35:1357-1366.
6. Klunk WE, Engler H, Nordberg A, Wang
Y, Blomqvist G, Holt DP, et al. Imaging
brain amyloid in Alzheimer's disease
with Pittsburgh Compound-B. Ann Neu-
rol. 2004;55:306-319.
7. Engler H, Forsberg A, Almkvist O,
Blomquist G, Larsson E, Savitcheva I,
et al. A Two-year follow-up of amyloid
deposition in patients with Alzheimer's
disease. Brain. 2006;129:2856-2866.
8. Newberg AB, Arnold SE, Wintering N,
Rovner BW, Alavi A. Initial clinical com-
parison of 18F-florbetapir and 18F-FDG
PET in patients with Alzheimer disease
and controls. J Nucl Med. 2012;53:902-
907.
9. Braak H, Braak E. Neuropathological
stageing of Alzheimer-related changes.
Acta Neuropathol 1991; 82:239–259.
10. Rowe CC, Ng S, Ackermann U, Gong SJ,
Pike K, Savage G, et al. Imaging beta-
amyloid burden in aging and dementia.
Neurology. 2007;68:1718-1725.
11. Villemagne VL, Pike KE, Darby D, Maruff
P, Savage G, Ng S, et al. Abeta depo-
sits in older non-demented individuals
with cognitive decline are indicative of
preclinical Alzheimer's disease. Neurop-
sychologia. 2008;46:1688-1697.
12. Jack CR Jr, Knopman DS, Jagust WJ, Pe-
tersen RC, Weiner MW, Aisen PS, et al.
Tracking pathophysiological processes
in Alzheimer's disease: an updated hy-
pothetical model of dynamic biomarkers.
Lancet Neurol. 2013;12:207-216.
13. Johnson KA, Minoshima S, Bohnen NI,
Donohoe KJ, Foster NL, Herscovitch P, et
al. Appropriate use criteria for amyloid
PET: a report of the Amyloid Imaging
Task Force, the Society of Nuclear Me-
dicine and Molecular Imaging, and the
Alzheimer's Association. Alzheimers De-
ment. 2013;9:e-1-16.
Carles Lorenzo Bosquet